Therapy Areas: Diabetes
Boehringer Ingelheim and Eli Lilly reveal clinical trial development program for Jardiance with EMPERIAL clinical trials
8 March 2018 -

Germany-based Boehringer Ingelheim and United States-based Eli Lilly have revealed plans to expand their clinical trial program for Jardiance in chronic heart failure with EMPERIAL clinical trials, it was reported yesterday.

These trials will assess the effect of Jardiance on exercise ability and heart failure symptoms in people with chronic heart failure, independent of whether they have type two diabetes.

EMPERIAL includes two Phase III trials that will evaluate the effect of 12 weeks of treatment with Jardiance on the ability of people with heart failure to perform daily exercise. The plans for the EMPERIAL trials follow initiation of the EMPEROR trials in March 2017. While the EMPEROR result trials concentrate on long-term morbidity and mortality results in people with heart failure, the EMPERIAL functional trials will investigate possible benefits on exercise capacity and heart failure symptoms. These studies are based on data received from the landmark EMPA-REG OUTCOME trial, where the effect of Jardiance on heart failure outcomes was assessed.

Login
Username:

Password: